In sum, our study exhibited that LINC‐PINT functioned as a tumor inhibitor during NSCLC progression and revealed a novel ceRNA regulatory pathway by sponging miR‐543 and activating PTEN. The gene discussed is LINC-PINT; the disease is neoplasm.